Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer

Acta Academiae Medicinae Sinicae

Volumn 32, Issue 4, 2010, Pages 421-423

  Cheng, Yue Juan ^a   Bai, Chun Mei ^a   Zhang, Zai Jun ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Department of Internal Medicine   (China)

Author keywords

Advanced; Efficacy; Erlotinib; Gemcitabine; Pancreatic cancer; Toxicities

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; HUMAN; LEUKOPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77957294815     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2010.04.013     Document Type: Article

References (13)

1. Parkin DM, Bray F, Ferley J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Li D, Xie K, Wolff R, et al. Pancreatic cancer [J]. Lancet, 2004, 363(9414): 1049-1057.
3. David C, Ian C. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer [J]. J Clin Oncol, 2009, 27(33): 5513-5518.
4. Malcolm M, David G, John H, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(15): 1960-1966.
5. Fjallskog MLH, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors [J]. Clin Cancer Res, 2003, 9(4): 1469-1473.
6. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis [J]. Int J Mol Med, 2003, 11(3): 305-309.
7. Xiong HQ. Molecular targeting therapy for pancreatic cancer [J]. Cancer Chemother Pharmacol, 2004, 54(suppl 1): S69-S77.
8. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic over-expression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma [J]. Pancreas, 2004, 29(1): E1-E8.
9. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma [J]. Cancer Res, 2000, 60(11): 2926-2935.
10. Ng SSW, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma [J]. Mol Cancer Ther, 2002, 1(10): 777-783.
11. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining [J]? J Oncol, 2005, 23(22): 5235-5246.
12. Saltz L, Kies M, Abbruzzese L, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies accross multiple malignancies [J]. Proc Am Soc Clin Oncol, 2003, 22(abstr 817): 204.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351(4): 337-345.